Abstract:Abstract Background: The efficacy of pemetrexed associates with the expression of folate enzymes, however, few serological marker is available to predict its efficacy. Moreover, dynamic monitoring of circulating tumor cell (CTC) count can predict the outcome of tumor therapy, the progress of tumor and the overall survival of the patient. By quantitative determination of folate receptor-positive CTCs, this study investigated the correlation of its baseline values to the efficacy of pemetrexed and performed a dynamic monitoring study in non-small cell lung cancer (NSCLC) patients who underwent first-line platinum-based chemotherapy. Methods: This study enrolled 70 NSCLC patients who received first-line platinum-based chemotherapy. The CTCs were quantified by negative enrichment using immunomagnetic beads in combination with folate receptor-directed polymerase chain reaction(PCR) that allows secondary amplification of tiny amounts of CTCs in peripheral blood, thereby enhancing the sensitivity of detection. In this study, the CTC levels were examined by collecting 3mL of anti-ENTA whole blood samples before the treatment and after every chemotherapy, and followed up until progressive disease (PD) or completion of first-line chemotherapy. Based on the changes in CTC levels, we evaluated the correlation of the changes in CTC levels and the progress of the disease as well as the correlation of the CTC levels and the therapeutic outcomes. Results: The CTC level of seventy patients was 13.68 CU/3mL. Of twenty-two patients who received pemetrexed disodium/platinum combined therapy (AP/AC), the patients harboring high levels of folate receptor showed greater efficacy than those with low expression levels (8.7 Conclusions: The patients with high expression of folate receptor-positive CTCs appear to have superior response to pemetrexed than those with low expression. Additionally, the changes of CTC count can be used as a dynamic monitoring indicator in the treatment process to evaluate tumor burden and therapeutic outcomes. Citation Format: Xiaoxia Chen, Caicun Zhou, Xuefei Li. Correlation of baseline value of folate receptor-positive circulating tumor cells and efficacy of pemetrexed and dynamic monitoring study in non-small cell lung cancer patients receiving first-line platinum-based chemotherapy. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2252.

Identification of Serum Biomarkers to Predict Pemetrexed/platinum Chemotherapy Efficacy for Advanced Lung Adenocarcinoma Patients by Data-Independent Acquisition (DIA) Mass Spectrometry Analysis with Parallel Reaction Monitoring (PRM) Verification.

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Pd-L1 Expression Indicates Favorable Prognosis for Advanced Lung Adenocarcinoma Patients Treated with Pemetrexed

Data from Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling

Prognostic Prediction of Pemetrexed-Platinum Chemotherapeutic Regimen for NSCLC by Serum Metabolomics.

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients

Evaluation of Plasma Microrna Levels to Predict Insensitivity of Patients with Advanced Lung Adenocarcinomas to Pemetrexed and Platinum

Prediction of platinum-based chemotherapy efficacy in lung cancer based on LC-MS metabolomics approach.

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma

Abstract 2252: Correlation of Baseline Value of Folate Receptor-Positive Circulating Tumor Cells and Efficacy of Pemetrexed and Dynamic Monitoring Study in Non-Small Cell Lung Cancer Patients Receiving First-Line Platinum-Based Chemotherapy

Serum Protein Pattern Could Predict the Therapeutic Effect of First-Line Pemetrexed/Cisplatin Chemotherapy in Patients with Lung Adenocarcinoma.

Proteomic Biomarker Predicts Therapeutical Effects of Oxaliplatin Combining with Fluoropyrimidine in Metastatic Gastric Cancer Patients by the SELDI-proteinchip Platform.

The Efficacy of Pemetrexed Combined Cis-platinum Chemotherapy for Patients with Advanced Non Small Cell Lung Cancer and the Effect on Serum Tumor Markers

Predictive Value of Unmethylated RASSF1A on Disease Progression in Non-Small Cell Lung Cancer Patients Receiving Pemetrexed-Based Chemotherapy

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

PD-L1 Expression is a Promising Predictor of Survival in Patients with Advanced Lung Adenocarcinoma Undergoing Pemetrexed Maintenance Therapy.

Identification of Candidate Molecular Markers Predicting Chemotherapy Resistance in Non-Small Cell Lung Cancer